Skip to main
LH

LH Stock Forecast & Price Target

LH Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Labcorp Holdings has demonstrated strong revenue growth, with its Central Lab segment achieving $554.7 million, reflecting a 7.5% increase, attributed to significant trial wins and advancements in digital pathology supported by AI. The company has an impressive backlog of $8.71 billion, marking a year-over-year increase of approximately 10%, alongside a trailing twelve-month net book-to-bill ratio of 1.11x, indicating robust future demand for its services. In the Diagnostic segment, Labcorp reported revenue of $2.75 billion, up 8.9% year-over-year, driven by balanced contributions from both organic growth and acquisitions, showcasing a strong operational performance.

Bears say

Labcorp Holdings faces significant risks that may adversely impact its financial performance, including potential adverse shifts in reimbursement policies under the Protecting Access to Medicare Act (PAMA) and challenges stemming from the integration of acquisitions. The company also encounters pressures from economic uncertainties and increased competition, which may further strain its market position. Additionally, regulatory challenges related to laboratory-developed tests (LDTs) could pose further threats to Labcorp's operational stability and profitability.

LH has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Labcorp Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Labcorp Holdings Inc (LH) Forecast

Analysts have given LH a Buy based on their latest research and market trends.

According to 12 analysts, LH has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $301.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $301.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Labcorp Holdings Inc (LH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.